Sex disparities and neutralizing-antibody durability to sars-cov-2 infection in convalescent individuals

Alena J. Markmann; Natasa Giallourou; D. Ryan Bhowmik; Yixuan J. Hou; Aaron Lerner; David R. Martinez; Lakshmanane Premkumar; Heather Root; David van Duin; Sonia Napravnik; Stephen D. Graham; Quique Guerra; Rajendra Raut; Christos J. Petropoulos; Terri Wrin; Caleb Cornaby; John Schmitz; Jo Ann Kuruc; Susan Weiss; Yara Park; Ralph Baric; Aravinda M. de Silva; David M. Margolis; Luther A. Bartelt

doi:10.1128/mSphere.00275-21

Sex disparities and neutralizing-antibody durability to sars-cov-2 infection in convalescent individuals

Alena J. Markmann, Natasa Giallourou, D. Ryan Bhowmik, Yixuan J. Hou, Aaron Lerner, David R. Martinez, Lakshmanane Premkumar, Heather Root, David van Duin, Sonia Napravnik, Stephen D. Graham, Quique Guerra, Rajendra Raut, Christos J. Petropoulos, Terri Wrin, Caleb Cornaby, John Schmitz, Jo Ann Kuruc, Susan Weiss, Yara ParkRalph Baric, Aravinda M. de Silva, David M. Margolis, Luther A. Bartelt

Research output: Contribution to journal › Article › peer-review

26 Scopus citations

Abstract

The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) has now caused over 2 million deaths worldwide and continues to expand. Currently, much is unknown about functionally neutralizing human antibody responses and durability to SARS-CoV- 2months after infection or the reason for the discrepancy in COVID-19 disease and sex. Using convalescent-phase sera collected from 101 COVID-19-recovered individuals 21 to 212 days after symptom onset with 48 additional longitudinal samples, we measured functionality and durability of serum antibodies. We also evaluated associations of individual demographic and clinical parameters with functional neutralizing antibody responses to COVID-19. We found robust antibody durability out to 6 months, as well as significant positive associations with the magnitude of the neutralizing antibody response and male sex and in individuals with cardiometabolic comorbidities.

Original language	English (US)
Article number	e00275-21
Journal	mSphere
Volume	6
Issue number	4
DOIs	https://doi.org/10.1128/mSphere.00275-21
State	Published - Aug 2021
Externally published	Yes

Keywords

Antibodies
Immunology
Neutralizing
Neutralizing antibodies
SARS-CoV-2

ASJC Scopus subject areas

Microbiology
Molecular Biology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1128/mSphere.00275-21

Cite this

Markmann, A. J., Giallourou, N., Bhowmik, D. R., Hou, Y. J., Lerner, A., Martinez, D. R., Premkumar, L., Root, H., van Duin, D., Napravnik, S., Graham, S. D., Guerra, Q., Raut, R., Petropoulos, C. J., Wrin, T., Cornaby, C., Schmitz, J., Kuruc, J. A., Weiss, S., ... Bartelt, L. A. (2021). Sex disparities and neutralizing-antibody durability to sars-cov-2 infection in convalescent individuals. mSphere, 6(4), Article e00275-21. https://doi.org/10.1128/mSphere.00275-21

Markmann, AJ, Giallourou, N, Bhowmik, DR, Hou, YJ, Lerner, A, Martinez, DR, Premkumar, L, Root, H, van Duin, D, Napravnik, S, Graham, SD, Guerra, Q, Raut, R, Petropoulos, CJ, Wrin, T, Cornaby, C, Schmitz, J, Kuruc, JA, Weiss, S, Park, Y, Baric, R, de Silva, AM, Margolis, DM & Bartelt, LA 2021, 'Sex disparities and neutralizing-antibody durability to sars-cov-2 infection in convalescent individuals', mSphere, vol. 6, no. 4, e00275-21. https://doi.org/10.1128/mSphere.00275-21

@article{5fba1760e27744d0b4fe288111eeefbf,

title = "Sex disparities and neutralizing-antibody durability to sars-cov-2 infection in convalescent individuals",

abstract = "The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) has now caused over 2 million deaths worldwide and continues to expand. Currently, much is unknown about functionally neutralizing human antibody responses and durability to SARS-CoV- 2months after infection or the reason for the discrepancy in COVID-19 disease and sex. Using convalescent-phase sera collected from 101 COVID-19-recovered individuals 21 to 212 days after symptom onset with 48 additional longitudinal samples, we measured functionality and durability of serum antibodies. We also evaluated associations of individual demographic and clinical parameters with functional neutralizing antibody responses to COVID-19. We found robust antibody durability out to 6 months, as well as significant positive associations with the magnitude of the neutralizing antibody response and male sex and in individuals with cardiometabolic comorbidities.",

keywords = "Antibodies, Immunology, Neutralizing, Neutralizing antibodies, SARS-CoV-2",

author = "Markmann, {Alena J.} and Natasa Giallourou and Bhowmik, {D. Ryan} and Hou, {Yixuan J.} and Aaron Lerner and Martinez, {David R.} and Lakshmanane Premkumar and Heather Root and {van Duin}, David and Sonia Napravnik and Graham, {Stephen D.} and Quique Guerra and Rajendra Raut and Petropoulos, {Christos J.} and Terri Wrin and Caleb Cornaby and John Schmitz and Kuruc, {Jo Ann} and Susan Weiss and Yara Park and Ralph Baric and {de Silva}, {Aravinda M.} and Margolis, {David M.} and Bartelt, {Luther A.}",

note = "Funding Information: This project was supported by the UNC Health Foundation and the North Carolina Policy Collaboratory at the University of North Carolina at Chapel Hill with funding from the North Carolina Coronavirus Relief Fund established and appropriated by the North Carolina General Assembly. The NIH SeroNet Serocenter of Excellence Award, U54 CA260543, supported generation of laboratory data and the following investigators: A.J.M., L.P., S.N., S.W., D.M.M., A.M.D.S., R.B., and L.A.B. A.J.M. was previously funded by an NIH NIAID T32 AI007151. S.N. is also funded by the following NIH grants: UNC Center for AIDS Research (P30 AI50410) and NA-ACCORD COVID-19 Supplement (U01 AI069918). D.R.M. is funded by NIH F32 AI152296 and a Burroughs Wellcome Fund Postdoctoral Enrichment Program Award and was previously funded by NIH NIAID T32 AI007151. Publisher Copyright: {\textcopyright} 2021 Markmann et al.",

year = "2021",

month = aug,

doi = "10.1128/mSphere.00275-21",

language = "English (US)",

volume = "6",

journal = "mSphere",

issn = "2379-5042",

publisher = "American Society for Microbiology",

number = "4",

}

TY - JOUR

T1 - Sex disparities and neutralizing-antibody durability to sars-cov-2 infection in convalescent individuals

AU - Markmann, Alena J.

AU - Giallourou, Natasa

AU - Bhowmik, D. Ryan

AU - Hou, Yixuan J.

AU - Lerner, Aaron

AU - Martinez, David R.

AU - Premkumar, Lakshmanane

AU - Root, Heather

AU - van Duin, David

AU - Napravnik, Sonia

AU - Graham, Stephen D.

AU - Guerra, Quique

AU - Raut, Rajendra

AU - Petropoulos, Christos J.

AU - Wrin, Terri

AU - Cornaby, Caleb

AU - Schmitz, John

AU - Kuruc, Jo Ann

AU - Weiss, Susan

AU - Park, Yara

AU - Baric, Ralph

AU - de Silva, Aravinda M.

AU - Margolis, David M.

AU - Bartelt, Luther A.

N1 - Funding Information: This project was supported by the UNC Health Foundation and the North Carolina Policy Collaboratory at the University of North Carolina at Chapel Hill with funding from the North Carolina Coronavirus Relief Fund established and appropriated by the North Carolina General Assembly. The NIH SeroNet Serocenter of Excellence Award, U54 CA260543, supported generation of laboratory data and the following investigators: A.J.M., L.P., S.N., S.W., D.M.M., A.M.D.S., R.B., and L.A.B. A.J.M. was previously funded by an NIH NIAID T32 AI007151. S.N. is also funded by the following NIH grants: UNC Center for AIDS Research (P30 AI50410) and NA-ACCORD COVID-19 Supplement (U01 AI069918). D.R.M. is funded by NIH F32 AI152296 and a Burroughs Wellcome Fund Postdoctoral Enrichment Program Award and was previously funded by NIH NIAID T32 AI007151. Publisher Copyright: © 2021 Markmann et al.

PY - 2021/8

Y1 - 2021/8

N2 - The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) has now caused over 2 million deaths worldwide and continues to expand. Currently, much is unknown about functionally neutralizing human antibody responses and durability to SARS-CoV- 2months after infection or the reason for the discrepancy in COVID-19 disease and sex. Using convalescent-phase sera collected from 101 COVID-19-recovered individuals 21 to 212 days after symptom onset with 48 additional longitudinal samples, we measured functionality and durability of serum antibodies. We also evaluated associations of individual demographic and clinical parameters with functional neutralizing antibody responses to COVID-19. We found robust antibody durability out to 6 months, as well as significant positive associations with the magnitude of the neutralizing antibody response and male sex and in individuals with cardiometabolic comorbidities.

AB - The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) has now caused over 2 million deaths worldwide and continues to expand. Currently, much is unknown about functionally neutralizing human antibody responses and durability to SARS-CoV- 2months after infection or the reason for the discrepancy in COVID-19 disease and sex. Using convalescent-phase sera collected from 101 COVID-19-recovered individuals 21 to 212 days after symptom onset with 48 additional longitudinal samples, we measured functionality and durability of serum antibodies. We also evaluated associations of individual demographic and clinical parameters with functional neutralizing antibody responses to COVID-19. We found robust antibody durability out to 6 months, as well as significant positive associations with the magnitude of the neutralizing antibody response and male sex and in individuals with cardiometabolic comorbidities.

KW - Antibodies

KW - Immunology

KW - Neutralizing

KW - Neutralizing antibodies

KW - SARS-CoV-2

UR - http://www.scopus.com/inward/record.url?scp=85115040415&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85115040415&partnerID=8YFLogxK

U2 - 10.1128/mSphere.00275-21

DO - 10.1128/mSphere.00275-21

M3 - Article

C2 - 34431693

AN - SCOPUS:85115040415

SN - 2379-5042

VL - 6

JO - mSphere

JF - mSphere

IS - 4

M1 - e00275-21

ER -

Sex disparities and neutralizing-antibody durability to sars-cov-2 infection in convalescent individuals

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this